Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Nov 15;102(10):1882–1891. doi: 10.1172/JCI4285

Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.

K R Cooke 1, G R Hill 1, J M Crawford 1, D Bungard 1, Y S Brinson 1, J Delmonte Jr 1, J L Ferrara 1
PMCID: PMC509139  PMID: 9819375

Abstract

Donor T cell responses to host alloantigen are known predictors for graft-versus-host disease (GVHD); however, the effect of donor responsiveness to an inflammatory stimulus such as lipopolysaccharide (LPS) on GVHD severity has not been investigated. To examine this, we used mouse strains that differ in their sensitivity to LPS as donors in an experimental bone marrow transplant (BMT) system. Lethally irradiated (C3FeB6)F1 hosts received BMT from either LPS-sensitive (LPS-s) C3Heb/Fej, or LPS-resistant (LPS-r) C3H/ Hej donors. Mice receiving LPS-r BMT developed significantly less GVHD as measured by mortality and clinical score compared with recipients of LPS-s BMT, a finding that was associated with significant decreases in intestinal histopathology and serum LPS and TNF-alpha levels. When donor T cell responses to host antigens were measured, no differences in proliferation, serum IFN-gamma levels, splenic T cell expansion, or CTL activity were observed after LPS-r or LPS-s BMT. Systemic neutralization of TNF-alpha from day -2 to +6 resulted in decreased intestinal pathology, and serum LPS levels and increased survival after BMT compared with control mice receiving Ig. We conclude that donor resistance to endotoxin reduces the development of acute GVHD by attenuating early intestinal damage mediated by TNFalpha. These data suggest that the responsiveness of donor accessory cells to LPS may be an important risk factor for acute GVHD severity independent of T cell responses to host antigens.

Full Text

The Full Text of this article is available as a PDF (592.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham L. J., French M. A., Dawkins R. L. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol. 1993 Apr;92(1):14–18. doi: 10.1111/j.1365-2249.1993.tb05940.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Antin J. H., Ferrara J. L. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992 Dec 15;80(12):2964–2968. [PubMed] [Google Scholar]
  3. Baker M. B., Altman N. H., Podack E. R., Levy R. B. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996 Jun 1;183(6):2645–2656. doi: 10.1084/jem.183.6.2645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blazar B. R., Taylor P. A., Linsley P. S., Vallera D. A. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood. 1994 Jun 15;83(12):3815–3825. [PubMed] [Google Scholar]
  5. Blazar B. R., Taylor P. A., Snover D. C., Sehgal S. N., Vallera D. A. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol. 1993 Nov 15;151(10):5726–5741. [PubMed] [Google Scholar]
  6. Braun M. Y., Lowin B., French L., Acha-Orbea H., Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med. 1996 Feb 1;183(2):657–661. doi: 10.1084/jem.183.2.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carroll M. C., Katzman P., Alicot E. M., Koller B. H., Geraghty D. E., Orr H. T., Strominger J. L., Spies T. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8535–8539. doi: 10.1073/pnas.84.23.8535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Christ W. J., Asano O., Robidoux A. L., Perez M., Wang Y., Dubuc G. R., Gavin W. E., Hawkins L. D., McGuinness P. D., Mullarkey M. A. E5531, a pure endotoxin antagonist of high potency. Science. 1995 Apr 7;268(5207):80–83. doi: 10.1126/science.7701344. [DOI] [PubMed] [Google Scholar]
  9. Cooke K. R., Kobzik L., Martin T. R., Brewer J., Delmonte J., Jr, Crawford J. M., Ferrara J. L. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996 Oct 15;88(8):3230–3239. [PubMed] [Google Scholar]
  10. D'Andrea A., Rengaraju M., Valiante N. M., Chehimi J., Kubin M., Aste M., Chan S. H., Kobayashi M., Young D., Nickbarg E. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992 Nov 1;176(5):1387–1398. doi: 10.1084/jem.176.5.1387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Down J. D., Mauch P., Warhol M., Neben S., Ferrara J. L. The effect of donor T lymphocytes and total-body irradiation on hemopoietic engraftment and pulmonary toxicity following experimental allogeneic bone marrow transplantation. Transplantation. 1992 Nov;54(5):802–808. doi: 10.1097/00007890-199211000-00007. [DOI] [PubMed] [Google Scholar]
  12. Eissner G., Kohlhuber F., Grell M., Ueffing M., Scheurich P., Hieke A., Multhoff G., Bornkamm G. W., Holler E. Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood. 1995 Dec 1;86(11):4184–4193. [PubMed] [Google Scholar]
  13. Ferrara J. L., Deeg H. J. Graft-versus-host disease. N Engl J Med. 1991 Mar 7;324(10):667–674. doi: 10.1056/NEJM199103073241005. [DOI] [PubMed] [Google Scholar]
  14. Fontaine P., Perreault C. Diagnosis of graft-versus-host disease in mice transplanted across minor histocompatibility barriers. Transplantation. 1990 Jun;49(6):1177–1179. doi: 10.1097/00007890-199006000-00032. [DOI] [PubMed] [Google Scholar]
  15. Fowler D. H., Kurasawa K., Husebekk A., Cohen P. A., Gress R. E. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol. 1994 Feb 1;152(3):1004–1013. [PubMed] [Google Scholar]
  16. Galanos C., Freudenberg M. A. Mechanisms of endotoxin shock and endotoxin hypersensitivity. Immunobiology. 1993 Apr;187(3-5):346–356. doi: 10.1016/S0171-2985(11)80349-9. [DOI] [PubMed] [Google Scholar]
  17. Gartner J. G., Merry A. C., Smith C. I. An analysis of pulmonary natural killer cell activity in F1-hybrid mice with acute graft-versus-host reactions. Transplantation. 1988 Dec;46(6):879–886. doi: 10.1097/00007890-198812000-00018. [DOI] [PubMed] [Google Scholar]
  18. Glode L. M., Rosenstreich D. L. Genetic control of B cell activation by bacterial lipopolysaccharide is mediated by multiple distinct genes or alleles. J Immunol. 1976 Dec;117(6):2061–2066. [PubMed] [Google Scholar]
  19. Haziot A., Rong G. W., Lin X. Y., Silver J., Goyert S. M. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol. 1995 Jun 15;154(12):6529–6532. [PubMed] [Google Scholar]
  20. Hill G. R., Cooke K. R., Teshima T., Crawford J. M., Keith J. C., Jr, Brinson Y. S., Bungard D., Ferrara J. L. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest. 1998 Jul 1;102(1):115–123. doi: 10.1172/JCI3132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hill G. R., Crawford J. M., Cooke K. R., Brinson Y. S., Pan L., Ferrara J. L. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997 Oct 15;90(8):3204–3213. [PubMed] [Google Scholar]
  22. Hill G. R., Krenger W., Ferrara J. L. The role of cytokines in acute graft-versus-host disease. Cytokines Cell Mol Ther. 1997 Dec;3(4):257–266. [PubMed] [Google Scholar]
  23. Holler E., Ertl B., Hintermeier-Knabe R., Roncarolo M. G., Eissner G., Mayer F., Fraunberger P., Behrends U., Pfannes W., Kolb H. J. Inflammatory reactions induced by pretransplant conditioning--an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation? Leuk Lymphoma. 1997 Apr;25(3-4):217–224. doi: 10.3109/10428199709114161. [DOI] [PubMed] [Google Scholar]
  24. Holler E., Kolb H. J., Mittermüller J., Kaul M., Ledderose G., Duell T., Seeber B., Schleuning M., Hintermeier-Knabe R., Ertl B. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood. 1995 Aug 1;86(3):890–899. [PubMed] [Google Scholar]
  25. Holler E., Kolb H. J., Möller A., Kempeni J., Liesenfeld S., Pechumer H., Lehmacher W., Ruckdeschel G., Gleixner B., Riedner C. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990 Feb 15;75(4):1011–1016. [PubMed] [Google Scholar]
  26. Jackson S. K., Parton J., Barnes R. A., Poynton C. H., Fegan C. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest. 1993 Sep;23(9):540–545. doi: 10.1111/j.1365-2362.1993.tb00963.x. [DOI] [PubMed] [Google Scholar]
  27. Jacob C. O., Fronek Z., Lewis G. D., Koo M., Hansen J. A., McDevitt H. O. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1990 Feb;87(3):1233–1237. doi: 10.1073/pnas.87.3.1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Johnsen H. E., Bostrom L., Moller J., Jorgensen J. A., Jensen L., Ringden O. A study of donor alloreactivity, which may predict acute graft-versus-host disease in HLA identical bone marrow transplantations for early leukaemia. Scand J Immunol. 1992 Mar;35(3):353–360. doi: 10.1111/j.1365-3083.1992.tb02868.x. [DOI] [PubMed] [Google Scholar]
  29. Kaminski E., Hows J., Man S., Brookes P., Mackinnon S., Hughes T., Avakian O., Goldman J. M., Batchelor J. R. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation. 1989 Oct;48(4):608–613. [PubMed] [Google Scholar]
  30. Klingemann H. G., Storb R., Fefer A., Deeg H. J., Appelbaum F. R., Buckner C. D., Cheever M. A., Greenberg P. D., Stewart P. S., Sullivan K. M. Bone marrow transplantation in patients aged 45 years and older. Blood. 1986 Mar;67(3):770–776. [PubMed] [Google Scholar]
  31. Krenger W., Cooke K. R., Crawford J. M., Sonis S. T., Simmons R., Pan L., Delmonte J., Jr, Karandikar M., Ferrara J. L. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation. 1996 Nov 15;62(9):1278–1285. doi: 10.1097/00007890-199611150-00018. [DOI] [PubMed] [Google Scholar]
  32. Krenger W., Snyder K. M., Byon J. C., Falzarano G., Ferrara J. L. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995 Jul 15;155(2):585–593. [PubMed] [Google Scholar]
  33. Lamping N., Dettmer R., Schröder N. W., Pfeil D., Hallatschek W., Burger R., Schumann R. R. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest. 1998 May 15;101(10):2065–2071. doi: 10.1172/JCI2338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Leturcq D. J., Moriarty A. M., Talbott G., Winn R. K., Martin T. R., Ulevitch R. J. Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest. 1996 Oct 1;98(7):1533–1538. doi: 10.1172/JCI118945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Lin T., Brunner T., Tietz B., Madsen J., Bonfoco E., Reaves M., Huflejt M., Green D. R. Fas ligand- mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease. J Clin Invest. 1998 Feb 1;101(3):570–577. doi: 10.1172/JCI896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. MacDonald G. C., Gartner J. G. Prevention of acute lethal graft-versus-host disease in F1 hybrid mice by pretreatment of the graft with anti-NK-1.1 and complement. Transplantation. 1992 Jul;54(1):147–151. doi: 10.1097/00007890-199207000-00026. [DOI] [PubMed] [Google Scholar]
  37. Mohler K. M., Torrance D. S., Smith C. A., Goodwin R. G., Stremler K. E., Fung V. P., Madani H., Widmer M. B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993 Aug 1;151(3):1548–1561. [PubMed] [Google Scholar]
  38. Nestel F. P., Price K. S., Seemayer T. A., Lapp W. S. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med. 1992 Feb 1;175(2):405–413. doi: 10.1084/jem.175.2.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Niederwieser D., Grassegger A., Auböck J., Herold M., Nachbaur D., Rosenmayr A., Gächter A., Nussbaumer W., Gaggl S., Ritter M. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood. 1993 Apr 15;81(8):2200–2208. [PubMed] [Google Scholar]
  40. Pape K. A., Khoruts A., Mondino A., Jenkins M. K. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol. 1997 Jul 15;159(2):591–598. [PubMed] [Google Scholar]
  41. Piguet P. F., Grau G. E., Allet B., Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med. 1987 Nov 1;166(5):1280–1289. doi: 10.1084/jem.166.5.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Price K. S., Nestel F. P., Lapp W. S. Progressive accumulation of bacterial lipopolysaccharide in vivo during murine acute graft-versus-host disease. Scand J Immunol. 1997 Mar;45(3):294–300. doi: 10.1046/j.1365-3083.1997.d01-404.x. [DOI] [PubMed] [Google Scholar]
  43. Remberger M., Ringden O., Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant. 1995 Jan;15(1):99–104. [PubMed] [Google Scholar]
  44. Remick D. G. Lung and gut injury induced by tumour necrosis factor. Res Immunol. 1993 Jun;144(5):326–331. doi: 10.1016/s0923-2494(93)80075-a. [DOI] [PubMed] [Google Scholar]
  45. Schwaighofer H., Kernan N. A., O'Reilly R. J., Brankova J., Nachbaur D., Herold M., Eibl B., Niederwieser D. Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation: influence of conditioning and hematopoietic reconstitution. Transplantation. 1996 Oct 15;62(7):947–953. doi: 10.1097/00007890-199610150-00013. [DOI] [PubMed] [Google Scholar]
  46. Sherry B., Cerami A. Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol. 1988 Oct;107(4):1269–1277. doi: 10.1083/jcb.107.4.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Snover D. C., Weisdorf S. A., Ramsay N. K., McGlave P., Kersey J. H. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology. 1984 Jan-Feb;4(1):123–130. doi: 10.1002/hep.1840040122. [DOI] [PubMed] [Google Scholar]
  48. Snover D. C., Weisdorf S. A., Vercellotti G. M., Rank B., Hutton S., McGlave P. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol. 1985 Apr;16(4):387–392. doi: 10.1016/s0046-8177(85)80232-x. [DOI] [PubMed] [Google Scholar]
  49. Storb R., Prentice R. L., Buckner C. D., Clift R. A., Appelbaum F., Deeg J., Doney K., Hansen J. A., Mason M., Sanders J. E. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983 Feb 10;308(6):302–307. doi: 10.1056/NEJM198302103080602. [DOI] [PubMed] [Google Scholar]
  50. Sultzer B. M., Castagna R., Bandekar J., Wong P. Lipopolysaccharide nonresponder cells: the C3H/HeJ defect. Immunobiology. 1993 Apr;187(3-5):257–271. doi: 10.1016/S0171-2985(11)80343-8. [DOI] [PubMed] [Google Scholar]
  51. Sultzer B. M., Goodman G. W. Endotoxin protein: a B-cell mitogen and polyclonal activator of C3H/HeJ lymphocytes. J Exp Med. 1976 Sep 1;144(3):821–827. doi: 10.1084/jem.144.3.821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Sviland L., Dickinson A. M., Carey P. J., Pearson A. D., Proctor S. J. An in vitro predictive test for clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 1990 Feb;5(2):105–109. [PubMed] [Google Scholar]
  53. Theobald M., Bunjes D., Nierle T., Arnold R., Heimpel H. Measurement of recipient-specific alloreactivity: is GVHD predictable? Bone Marrow Transplant. 1993;12 (Suppl 3):S18–S23. [PubMed] [Google Scholar]
  54. Theobald M., Nierle T., Bunjes D., Arnold R., Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med. 1992 Dec 3;327(23):1613–1617. doi: 10.1056/NEJM199212033272301. [DOI] [PubMed] [Google Scholar]
  55. Thiéblemont N., Wright S. D. Mice genetically hyporesponsive to lipopolysaccharide (LPS) exhibit a defect in endocytic uptake of LPS and ceramide. J Exp Med. 1997 Jun 16;185(12):2095–2100. doi: 10.1084/jem.185.12.2095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Tough D. F., Sun S., Sprent J. T cell stimulation in vivo by lipopolysaccharide (LPS). J Exp Med. 1997 Jun 16;185(12):2089–2094. doi: 10.1084/jem.185.12.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Trepicchio W. L., Wang L., Bozza M., Dorner A. J. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol. 1997 Dec 1;159(11):5661–5670. [PubMed] [Google Scholar]
  58. Vella A. T., Mitchell T., Groth B., Linsley P. S., Green J. M., Thompson C. B., Kappler J. W., Marrack P. CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J Immunol. 1997 May 15;158(10):4714–4720. [PubMed] [Google Scholar]
  59. Watson J., Kelly K., Largen M., Taylor B. A. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol. 1978 Feb;120(2):422–424. [PubMed] [Google Scholar]
  60. Weisdorf D., Hakke R., Blazar B., Miller W., McGlave P., Ramsay N., Kersey J., Filipovich A. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991 Jun;51(6):1197–1203. doi: 10.1097/00007890-199106000-00010. [DOI] [PubMed] [Google Scholar]
  61. Xun C. Q., Thompson J. S., Jennings C. D., Brown S. A., Widmer M. B. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood. 1994 Apr 15;83(8):2360–2367. [PubMed] [Google Scholar]
  62. van Bekkum D. W., Knaan S. Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst. 1977 Mar;58(3):787–790. doi: 10.1093/jnci/58.3.787. [DOI] [PubMed] [Google Scholar]
  63. van Bekkum D. W., Roodenburg J., Heidt P. J., van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst. 1974 Feb;52(2):401–404. doi: 10.1093/jnci/52.2.401. [DOI] [PubMed] [Google Scholar]
  64. van Els C. A., Bakker A., Zwinderman A. H., Zwaan F. E., van Rood J. J., Goulmy E. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. I. Absence of correlation with cytotoxic effector cells. Transplantation. 1990 Jul;50(1):62–66. doi: 10.1097/00007890-199007000-00011. [DOI] [PubMed] [Google Scholar]
  65. van Els C. A., Bakker A., Zwinderman A. H., Zwaan F. E., van Rood J. J., Goulmy E. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. II. Evidence of a possible involvement of proliferative T cells. Transplantation. 1990 Jul;50(1):67–71. doi: 10.1097/00007890-199007000-00012. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES